ATC/DDD alterations 2017
New ATC codes 2017
New DDDs 2017
ATC alterations
|
A10BX04 |
exenatide |
A10BJ01 |
|
A10BX07 |
liraglutide |
A10BJ02 |
|
A10BX09 |
dapagliflozin |
A10BK01 |
|
A10BX10 |
lixisenatide |
A10BJ03 |
|
A10BX11 |
canagliflozin |
A10BK02 |
|
A10BX12 |
empagliflozin |
A10BK03 |
|
A10BX13 |
albiglutide |
A10BJ04 |
|
A10BX14 |
dulaglutide |
A10BJ05 |
|
B02BD09 |
nonacog alfa |
B02BD04 1) |
|
B02BD12 |
trenonacog alfa |
B02BD04 1) |
|
L01BA01 |
methotrexate |
L04AX03 2) |
|
L04AC06 |
mepolizumab |
R03DX09 |
|
R05CB12 |
tiopronin |
G04BX16 |
Existing ATC code B02BD04 coagulation factor IX
Splitting of ATC code. Only the classification of pre-filled syringe/pen of methotrexate for use in non-cancer indications is changed. These products will be moved to the existing ATC code for oral administered product of methotrexate. Parenteral preparations used for treatment of cancer will remain in L01BA01.Other ATC alterations
|
A10BJ |
Glucagon-like peptide-1 (GLP-1) analogues |
||
|
A10BK |
Sodium-glucose co-transporter 2 (SGLT2) inhibitors |
||
|
C07FX |
Beta blocking agents, other combinations |
||
|
N02AJ 1) |
Opioids in combination with non-opioid analgesics |
||
|
C07AA57 |
sotalol, combinations |
C07FX02 |
sotalol and acetylsalicylic acid |
|
C07AB52 |
metoprolol, combinations |
C07FX03 |
metoprolol and acetylsalicylic acid |
|
C07AB57 |
bisoprolol, combinations |
C07FX04 |
bisoprolol and acetylsalicylic acid |
|
C07F |
Beta blocking agents and other antihypertensives |
C07F |
Beta blocking agents, other combinations |
|
C07FA |
Beta blocking agents, non-selective, and other antihypertensives |
Deleted |
|
|
C07FA05 |
propranolol and other antihypertensives |
C07FX01 |
propranolol and other combinations |
|
C07FB |
Beta blocking agents, selective, and other antihypertensives |
C07FB |
Beta blocking agents and calcium channel blockers |
|
C07FB02 2) |
metoprolol and other antihypertensives |
C07FB02 |
metoprolol and felodipine 3) |
|
C07FB03 |
atenolol and other antihypertensives |
C07FB03 |
atenolol and nifedipine |
|
C07FB07 |
bisoprolol and other antihypertensives |
C07FB07 |
bisoprolol and amlodipine |
|
C07FB12 |
nebivolol and other antihypertensives |
C07FB12 |
nebivolo and amlodipine |
|
M01AE51 1) |
Ibuprofen, combinations |
N02AJ03 N02AJ08 |
dihydrocodeine and other non-opioid analgesics |
|
N02AA55 1) |
oxycodone, combinations |
N02AA55 |
oxycodone and naloxone |
|
N02AA58 1) |
dihydrocodeine, combinations |
N02AJ01 N02AJ03 |
dihydrocodeine and paracetamol |
|
N02AA59 1) |
codeine, combinations excl. psycholeptics |
N02AJ06 |
codeine and paracetamol |
|
N02AX52 |
tramadol, combinations |
N02AJ13 |
tramadol and paracetamol |
|
N02BA51 1) |
acetylsalicylic acid, combinations excl. psycholeptics |
N02AJ02 N02AJ07 |
dihydrocodeine and acetylsalicylic acid |
|
N02BE51 1) |
paracetamol, combinations excl. psycholeptics |
N02AJ01 N02AJ17 |
dihydrocodeine and paracetamol |
Splitting of ATC codes according to contents of the different fixed combinations of opioids and other analgesics. The ATC codes in N02A, N02BA51, N02BE51 and M01AE51 will be maintained for other combinations. Combinations with opioids and non-opioid analgesics currently classified in the following ATC codes N02AA55, N02AA58, N02AA59 will be moved to the new ATC 4th level N02AJ. All the existing combination codes will be kept in N02A since there may be other combinations without analgesics available (e.g. oxycodone and naloxone will remain in N02AA55). The ATC classification of all low dose (<20 mg dose) combinations products of codeine or dihydrocodeine currently classified in N02B or M01A will be altered to the new ATC codes in N02AJ.
Splitting of ATC code in connection with alterations in C07FX.
Unchanged ATC code, ATC level name changed.DDD alterations
|
A16AX01 |
thioctic acid |
0.2 |
g O,P |
0.6 |
g O,P |
|
B02BD |
Blood coagulation factors |
deleted 1) |
|||
|
G03XB01 |
mifepristone |
0.6 |
g O |
0.2 |
g O |
|
J01CR01 |
ampicillin and enzyme inhibitor |
2 |
g 2) P |
6 |
g 2) P |
|
J02AC04 |
posaconazole |
0.8 |
g O |
0.3 |
g O |
|
R03BB04 |
tiotropium bromide |
18 |
mcg 3) Inhal.powder |
10 |
mcg 3) Inhal.powder |
|
V03AE07 |
calcium acetate |
2 |
g O |
6 |
g O |
DDDs for the various blood coagulation factors in all ATC 5th level codes in B02BD are deleted. No new DDDs will be established in B02BD Blood coagulation factors.
Refers to ampicillin
The DDD for tiotropium bromide is unchanged but has been defined as the content of one inhalation capsule (18 mcg) as tiotropium. Since there are different inhalation capsules on the market containing different amounts of active substance, the DDD is now defined as the delivered dose, which is the same (10 mcg) as tiotropium for all products.
Last updated: 2017-01-12
Источник: Фармацевтическое обозрение Казахстана со ссылкой на редакцию "КНФ".
